Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan-Feb;37(1):185-190.
doi: 10.12669/pjms.37.1.2950.

Effects of etibatide combined with emergency percutaneous coronary intervention on blood perfusion and cardiac function in patients with acute myocardial infarction

Affiliations

Effects of etibatide combined with emergency percutaneous coronary intervention on blood perfusion and cardiac function in patients with acute myocardial infarction

Ying Hu et al. Pak J Med Sci. 2021 Jan-Feb.

Abstract

Objectives: To investigate the effects of etibatide combined with emergency percutaneous coronary intervention (PCI) on blood perfusion and cardiac function in acute myocardial infarction (AMI) patients.

Methods: This was a prospective, randomized, controlled study. From November 2015 to June 2019, 196 patients with ST-segment elevation myocardial infarction (STEMI) undergoing emergency PCI admitted to Baoding First Central Hospital were enrolled. The 196 STEMI patients were randomly divided into experimental group and control group. In the experimental group, STEMI patients were treated with emergency PCI + etibatide; while in the control group, only PCI was performed. Observation indexes included: general data, myocardial perfusion and cardiac function indexes and major adverse cardiac events (MACE).

Results: There was no significant difference in general data between the two groups (P > 0.05). The rate of ST-segment resolution (STR) in the experimental group was better than that in the control group (P < 0.05). In myocardial contrast echocardiography (MCE), higher peak intensity (PI) and shorter time-to-peak (TP) were observed in the experimental group compared with the control group (P < 0.05). The platelet aggregation rate was compared between the two group at the time points of before PCI, after PCI and two hour after drug withdrawal, and there was no significant change in the platelet aggregation rate of the control group between different time points (before PCI, after PCI and two hour after drug withdrawal); while the platelet aggregation rate of the experimental group was significantly lower after PCI and two hour after drug withdrawal than that before PCI (P < 0.05), and an obviously decreased platelet aggregation rate was found in the experimental group(P < 0.05). After three months of follow-up, there was one case of MACE in the experimental group and 1 case of MACE in the control group, without any difference in the incidence of MACE between the two groups (P > 0.05).

Conclusion: Etibatide combined with emergency PCI could improve myocardial reperfusion and cardiac function in patients with acute STEMI without increasing the incidence of MACE.

Keywords: Acute myocardial infarction; Cardiac function; Etibatide; Myocardial contrast echocardiography.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interest: None.

Similar articles

Cited by

References

    1. Zhai XB, Gu ZC, Liu XY. Clinical pharmacist intervention reduces mortality in patients with acute myocardial infarction:A propensity score matched analysis. Eur J Hosp Pharm. 2019;26(5):248–252. doi:10.1136/ejhpharm-2017-001344. - PMC - PubMed
    1. Lev EI, Kornowski R, Teplisky I, Hasdai D, Rechavia E, Shor N, et al. The impact of adjunctive eptifibatide therapy with percutaneous coronary intervention for acute myocardial infarction. Int J Cardiovasc Intervent. 2005;7(1):41–45. doi:10.1080/14628840510011180. - PubMed
    1. O'Shea C, Tcheng JE. Platelet glycoprotein IIb/IIIa integrin inhibition in acute myocardial infarction. J Invasive Cardiol. 1999;11(8):494–499. - PubMed
    1. Kleiman NS, Tracy RP, Talley JD, Sigmon K, Joseph D, Topol EJ, et al. Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. J Thromb Thrombolysis. 2000;9(1):5–12. doi:10.1023/a:101⇊123272. - PubMed
    1. O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention:a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol. 2009;54(8):678–685. doi:10.1016/j.jacc.2009.05.025. - PubMed

LinkOut - more resources